GI Cancer
Novel approach delivers quality-of-life benefits for patients with pancreatic cancer
Palliative radiation therapy improves hepatic pain in HCC and liver metastasis
Improved survival following postoperative sorafenib plus TACE in HCC
Quality-of-life benefits for tislelizumab in uHCC
Stereotactic body radiation therapy beneficial for patients with locally advanced HCC
SWOG 1815, first-ever phase 3 trial in BTC, fails
IMbrave 151 missed primary endpoint in advanced BTC
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC
Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC
Mutation-based selection to identify patients suitable for panitumumab treatment
Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC
Does cell-free DNA influence MRD testing in post-operative colon cancer?
OPERA: surgery may be avoided with adequate therapy in rectal cancer
Can we improve total neoadjuvant therapy for rectal cancer?
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer
Regorafenib offers survival benefit for patients with pre-treated gastric cancer
Radiotherapy or not in locally advanced oesophageal or junctional cancer?
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer
3-year follow-up data confirms benefits of nivolumab plus chemotherapy
Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer
Promising phase 2 results for HER-Vaxx in gastric cancer
Novel regimen may avoid TME surgery in rectal cancer
Palliative radiation therapy improved hepatic pain in HCC and liver metastasis
Immunotherapy response may be modulated by microbiome
Computer-aided colonoscopies improved adenoma detection rates
Benefit of colon cancer screening with colonoscopy lower than anticipated
Screening-detected colorectal cancers may have superior surgical outcomes
Detection of Europe´s deadliest cancer: much room for improvement
Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC
New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations
Chemo-immunotherapy in gastric cancer is more effective when administered in parallel
High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer
Fruquintinib: a potential new treatment for patients with refractory mCRC
Second-line avelumab is effective in patients with MSI-H/dMMR mCRC
Trastuzumab-deruxtecan Potential Second-line Therapy Option in HER2-Positive Gastric Cancer
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer
Spectacular results for dostarlimab in mismatch repair deficient rectal cancer
Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases
To resect or not to resect primary tumours in stage IV colon cancer?
Novel treatment option for KRAS wildtype pancreatic cancer
Substantial increase of oesophageal cancer prevalence in the middle-aged
Cancer detection likely similar for one-time colonoscopy or two fecal immunochemical tests
Metastasis rate high after endoscopic resection of high-risk T1a esophageal cancers
Cumulative exposure to tacrolimus tied to post liver transplant cancer risk
Sintilimab plus FOLFIRINOX may provide benefits in metastatic pancreatic cancer
TRYbeCA-1: Eryaspase + chemotherapy does not meet primary endpoint in pancreatic cancer
Persisting disparities in pancreatic cancer care
ctDNA promising biomarker for recurrence of pancreatic cancer
Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma
EMR versus ESD in oesophageal cancer
Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer
AK104 plus chemotherapy promising first-line option for gastric cancer
DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer
The emerging role of AI in gastroesophageal cancer
DCF outperforms standard-of-care for locally advanced oesophageal cancer
Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome
Updates on pembrolizumab for oesophageal and gastric cancer
NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC
Dostarlimab may offer an alternative for dMMR rectal cancer
DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC
Key updates in colorectal cancer screening
Impact of COVID-19 on screening for colorectal cancer
Nivolumab plus standard-of-care does not meet primary endpoint for mCRC
No benefit of additional oxaliplatin in elderly patients with mCRC
Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled
Long-course chemoradiation versus short-course radiotherapy in rectal cancer
Adjuvant S-1 therapy superior to observation in resected biliary tract cancer
Analysis of metastasectomy in CRC reveals benefits and disparities
Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma
EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo
TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer
HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC
LAUNCH: TACE plus lenvatinib efficacious in advanced HCC
Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC
p53 mRNA nanotherapy plus anti-PD-1 therapy reverse immunosuppression in a liver cancer model
Sponge-on-a-string device helps detect, monitor early esophageal neoplasia
Early-onset colorectal cancer in young patients is often advanced at diagnosis
BRCA1/2 pathogenic variants linked to prostate, pancreatic and stomach cancers
No benefit to adding trastuzumab to neoadjuvant chemoradiation for HER2 esophageal cancer
Neoadjuvant cemiplimab promising for resectable liver cancer
Overweight, obesity in early adulthood tied to higher risk of early-onset colorectal cancer
Immune checkpoint inhibitors likely best standard therapies for unresectable liver cancer
CRISPR/Cas9 gene editing boosts effectiveness of sonodynamic therapy for liver cancer in mice
Pre-op chemosensitivity tied to post-op survival in patients with gastric tumors
Lowering of CRC-screening age likely to affect colonoscopy demand, case mix, adenoma detection
Belzutifan shows benefit in two conditions that spark tumor growth
Diet that promotes sulfur-metabolizing bacteria tied to colorectal cancer risk
A single flexible sigmoidoscopy screening tied to long-term protection against colorectal cancer
Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC
Immune chemo-sensitisation looks promising in microsatellite-stable mCRC
Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC
Automated detection of microsatellite status on unstained samples in early colon cancer
Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer
HIPEC in gastric cancer with peritoneal metastases
ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer
External-beam radiation underused in people with liver cancer awaiting transplant
More adults embraced at-home colorectal-cancer screening during pandemic
Add-on ramucirumab increases PFS, not overall survival, in East Asians with advanced gastric cancer
Adenomas detected per colonoscopy a valid quality measure tied to lower post-colonoscopy CRC
Rising rates of esophageal cancer in young adults, lifestyle may be to blame
Relatives of patients with colorectal carcinoma in situ at higher risk for colorectal cancer
ESMO 2021 Highlights Podcast
Antibiotics tied to increased risk of colorectal cancer
Combined chemoembolization and ablation effective for early-stage hepatocellular carcinoma
Mirati drug combination shrinks tumors in 39% of colon cancer patients in study
New guidelines provide framework for safe liver transplantation for non-resectable colorectal liver metastases
Screening and treating H. pylori in those at high risk for gastric cancer appears cost-effective
More-aggressive therapy not warranted for early-onset colorectal cancer
Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer
Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC
Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC
Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer
Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC
AI improves detection of gastric neoplasms during routine endoscopies
Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective
Pertuzumab plus trastuzumab promising in HER2-positive biliary-tract cancers
Perioperative SOX protocol bests adjuvant CapOx in locally advanced gastric cancer
Study supports chemopreventive effect of statins on liver cancer in NASH cirrhosis
Donafenib yields survival advantage over sorafenib in Chinese patients with advanced liver cancer
Increased risk of rectal cancer after colectomy in IBD
Risk of colorectal cancer is detected by low-pass whole genome sequencing
Apatinib boosts survival in Chinese patients with advanced liver cancer
Patients with advanced esophageal cancer can skip chemo with upfront dual immunotherapy combo
PARP inhibitor rucaparib helps shrink pancreatic tumors with mutations
Stool-based tests boosted declining screening rates for colorectal cancer during pandemic
Adding aprepitant to other antiemetics further prevents chemo-induced nausea and vomiting
HER2 results in gastric cancer often differ between labs with implications for treatment
Chemoprevention with low-dose aspirin promising in familial adenomatous polyposis
Surgery after chemo can improve survival in stage 2 pancreatic cancer
Nivolumab doubles disease-free survival when residual esophageal cancer lurks
Hypofractionated ablative radiation tied to improved survival in pancreatic cancer
Liquid biopsy after hepatectomy promising aid in metastatic colorectal cancer
First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC
Short-course radiotherapy with delayed surgery better for elderly rectal cancer patients
Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels
Circulating tumour DNA predicts recurrence in colorectal cancer
Gut microbiome DELIVERs nivolumab forecast in gastric cancer
Ivosidenib in second-line improves OS in IDH1-mutant cholangiocarcinoma
Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results
OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward
Prognostic value of tumour deposits in stage 3 colon cancer patients
Final phase 2 results of second-line infigratinib for advanced cholangiocarcinoma
Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer
Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC
Adjuvant nivolumab: good quality-of-life
Preliminary surgery salvage data after watch & wait policy from OPERA trial
Landmark OS for HCC, updated IMbrave150 data
Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse
Second-line pembrolizumab after progression on sorafenib benefits OS/PFS in advanced HCC
Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers
Phase 2 study supports first-line pembrolizumab in advanced HCC
Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy
Yttrium-90 (Y-90) glass microspheres for HCC
Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC
Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy
Sorafenib extends PFS, but not OS, for HCC transcatheter arterial chemoembolisation
Zanidatamab provides ORR in HER2+ biliary tract cancer
Borderline resectable pancreatic cancer: phase 2 results
No survival benefit for olaparib in BRCA-mutated metastatic pancreatic cancer
Metastatic pancreatic adenocarcinoma: second-line naI-IRI plus 5-FU/LV
COVID-19 impact on gastrointestinal cancer care
Treatment delay for cholangiocarcinoma adjuvant therapy does not affect OS
No benefit of adding axitinib to ocreotide acetate in non-pancreatic neuroendocrine tumours
Phase 2 abemaciclib trial in patients with advanced NETs
Neoadjuvant chemo for intrahepatic cholangiocarcinoma may prolong life
No survival benefit to primary resection before chemo in metastatic colorectal cancer
Drug combo yields longest-ever survival in advanced liver cancer
Radiotherapy for rectal cancer linked to risk for later malignant gynecological neoplasms
Organ preservation possible in early-stage rectal cancer
Radiotherapy then chemotherapy before surgery may be best in rectal cancer
Carcinoid tumors increasing in young adults at a faster clip than adencarcinomas
No survival differences with open or laparoscopic surgery for liver metastases
Risk-adapted starting ages proposed for colorectal cancer screening in diabetics
Pembrolizumab prolongs overall survival in some with advanced esophageal cancer
Adenoma detection rate improves over time
Post-colonoscopy colorectal cancers in IBD patients
Colorectal cancer more likely after first acute diverticulitis
Linked color imaging bests conventional imaging for upper GI cancer detection
Invasive features, positive margins tied to worse outcome of precancerous pancreas lesions
Surufatinib improves progression-free survival in advanced pancreatic neuroendocrine tumors
MR-Linac-delivered adaptive radiation therapy promising in pancreatic cancer
Vascular invasion, tumor deposits more prognostic than TNM for rectal cancer
HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan
Pembrolizumab as first-line in MSI-H mCRC
REGOMUNE: a phase 2 study combining regorafenib and avelumab
Cardiotoxicity: consider switching to S-1
Perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma
Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC
Eflornithine-sulindac combo may not offer extra benefit for familial adenomatous polyposis
Role of immune cells in intestinal fibrosis
Increased risk of small bowel cancer in IBD
Increased incidence of colorectal cancer and death in CD
Risk of rectal, anal cancer increased in perianal CD
Glyco-fingerprint as risk factor of UC-associated cancer
Mixed data: AMG 510 in tumours with KRASG12C
Preoperative chemotherapy for colon cancer
Nivolumab improves OS in advanced oesophageal cancer
